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Background/Aims: It remains controversial whether
Helicohacter pylori infection causes .symptoms in non-
ulcer dyspepsia. One hundred non-ulcer dyspepsia pa-
tients were .screened for H. pylori infection hetween No-
vember 1989 and February 1994. Forty patients entered
a trial where hoth infected and uninfected patients were
treated with H. pylori therapy, with the uninfeeted group
serving as controls. Methods: Non-uleer dyspepsia was
defined as unexplained epigastric discomfort lasting for
at least 4 wk. From November 1989 until February 1992,
all patients, regardless of H. pylori status, were treated
with hismuth suhsalicylate tablets (524 mg q.i.d.) for 4
wk and metronidazole (250 mg q.i.d.) for the first 2 of the
4 wk. From March 1992 until February 1994, only in-
fected patients were treated in an attempt to obtain
equal numbers in each group. //. pylori infection was
diagnosed histologically at the index endoscopy and 1
month after completion of therapy. Symptoms were
scored on a 0-5 seale for both frequency and severity.
Results: Of 100 patients screened, 33 were infected with
H. pyhri (mean age, 42; 10 men, 23 women), and 67 were
uninfected (mean age, 38; 16 men, 51 women). Thirty-six
uninfected patients were not offered treatment during
the latter part of the trial. Of the remaining 31 unin-
fected patients, 10 dropped out; of the 3i infected pa-
tients, 14 dropped out. Twenty-one uninfected patients
and 19 H. pylori-'mt'ecte6 patients completed treatment;
in 13 of 19 patients (68%), H. pylori was eradicated.
Symptoms improved in eight of 13 (61%) H. pylori-
eradicated patients and in four of six (66%) //. pylori-
persistent patients, compared with 14 of 21 (66%) un-
infected patients. Long-term follow-up (mean, 34
months) showed similar .symptom outcome in the two
treatment groups. Conclusions: Thirty-three percent of
our non-ulcer dyspepsia patients were infected with H.
pylori, a number similar to the percentage of infected
age-matched controls in the U.S. Treatment with bis-
muth subsaiicylate and metronidazole resulted in symp-
tomatic improvement in 61-66% of non-ulcer dyspepsia
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patients regardless of initial or post-treatment //. pylori
status. Long-term symptom follow-up in both the control
and infected groups gave similar results. //. pylori infec-
tion is not related to the symptoms of non-ulcer dyspep-
sia.
INTRODUCTION
II has been estimated thai chronic dyspepsia affects 15%
of the adult population and that 25% of these will seek
medical attention {I}. Most of these patients will not have
peptic ulcers or other organic disease. These patients have
been labeled as non-uleer, functional, or essential dyspepsia
patients (2-4). They have been shown to have a high pla-
ecbo response rate and a poor response to acid suppressive
therapy (5, 6). Several factors make chronic infection with
Heiicobacwr pylori an attractive potential etiology of symp-
toms in at least a subset of these patienls. First, it is known
that acute infection with H. pylori often causes acute dys-
pepsia (7). Second, it is reported that the prevalence of H.
pylori infection is higher in non-ulcer dyspepsia (NUD)
patients than in controls (8). Third, H. pylori is the accepted
eause of almost all histologieal chronic active gastritis (9).
Fourth, H. pylori infection is closely associated with peptic
ulcer disease. Despite these four reasons why H. pylori
infection should cause NUD, controlled studies of symptom
outcome after H. pylori treatment have had conflicting re-
sults (10). This has led to the conclusion that routine testing
for H. pylori in the absence of ulcer disease is not warranted
(II) and that further study of the relationship between the
symptoms of NUD and H. pylori is needed (12).
We describe the long-term follow-up of symptoms in
NUD patients who were all treated as if they had H. pylori
infection with metronidazole and bismuth subsaiicylate re-
gardless of whether ihey were initially infected. The H.
/n/rJ/V-negative patients were used as controls.
MATERIALS AND METHODS
Non-ulcer dyspepsia was defined as unexplained epigas-
tric discomfort lasting for at least 4 wk. Patients were
1089
1090 ELTA (•/ al. AJG- Vol. 90, No. 7. J995
excluded if their predominant symptoms were reflux-like
(frequent heartburn, acid reflux) or dysmotility-like (bloat-
ing, nausea). The patients were all studied at the University
of Michigan Medicai Center. Most had previous thorough
diagnostic evaluations and had failed prior medical therapy
including H^ blockers. One hundred NUD patients were
screened for H. pylori infection by antral biopsy for histol-
ogy at their normal upper endoscopies between November
108*-̂  and February 1994, and they agreed to study partici-
pation. None had previously been treated for H. pylori
infection. From study initiation until February 1992, all
patients, regardless of their H. pytori status, were given the
study treatment. Both the patients and the investigators were
blinded to the results ofthe initial histological determination
of H. pylori status until after the follow-up endoscopy.
Interim review of results after entering 48 patients revealed
that too few H. pylori-infected patients were being studied.
Therefore, from February 1W2 until the study close in
February 1994, only H. /jy/on-infected patients were offered
study entry. During this second half of the study, neither
patients nor investigators were blinded to the initial pres-
ence of infection. This second portion of the study included
16 H. py/orMnfected individuals, eight of whom completed
the study.
Three antral biopsies were obtained at the entry endos-
copy and at the follow-up endoscopy, which was performed
I month after completion of therapy. The presence of H.
pylori was determined histologicaily by one pathologist
after review of hematoxylin and eosin stains on all biopsies
and Warthin-Starry stains on the inflamed biopsies that were
H. />y/rt//-negative by hematoxylin and eosin staining. Bi-
opsies were graded on the severity of plasma cell Infiltration
(chronic inflammation) as follows: 0, normal; 1, focal su-
perficial involving the pit compartment; 2, diffuse superfi-
cial; 3, midmucosal extending into the middle of the mu-
cosa; 4, transmucosal. The presence of polymorphonuclear
cells in the pit epithelium was also graded as present or
absent.
Patients were treated with bismuth subsalicylate tablets
(524 mg (i.i.d.) for 4 wk and metronidazole (250 mg q.i.J.)
for the first 2 of the 4-wk treatment period. Medication
compliance was determined by pill counts at the follow-up
endoscopy.
At study entry, the following data were obtained: patient
age and race, prior history of ulcer disease (by patient
history; documentation of prior ulcer was not obtained),
prior use of anti-ulcer medicines (antacids, Hj-blockers,
omeprazole, or sucralfate), daily use of cigarettes, at least
weekly use of alcohol, and use of aspirin and nonsteroidal
anti-inflammatory drugs. Symptoms were assessed at three
time points: at study entry, at the follow-up endoscopy (1
month after treatment completion), and on long-term fol-
low-up. Four symptoms were scored on a 0-5 scale for both
frequency and severity: pain, nausea and vomiting, bloating/
belching/gas, and anorexia. The symptom scale for fre-
quency was graded as follows: 0, none; 1, 1 d/wk; 2, 2-3
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None of these entry characteri.slics were
infected versus noninfetled groups.
statistically different in the
days; 3,4-5 days: 4, 6-7 days; 5, 4-7 days and 4-7 nights.
The symptom seale for severity was graded as follows: 0,
none; 1, mild and aware of symptom; 2, mild to moderate;
3, moderate and interferes with routine; 4, severe; 5, un-
bearable. Symptom improvement was defined subjectively
as an improvement of three or more points in the pain score
when the frequency and severity scores were added to-
gether. All of our patients who met this criteria felt ihat ihcy
had global improvement. The other symptoms {i.e.. nausea,
bloating, and anorexia) were not used in this improvement
determination, because not all patients had all of these
symptoms. Patients also were asked to keep a daily diary of
symptoms while taking medications and to report a single
score on a 0-5 scale for overall symptoms.
Statistical analysis was perlbrmed using the Student's t
test and the x~ 'cst with Yates correction. This study was
approved by the Institutional Review Board at the Univer-
sity of Michigan.
RESULTS
Entry characteristics for the 100 patients screened are
listed in Table 1. Thirty-three patients were infected with H.
pylori, and 67 had no histologieal evidence for infection.
The mean age of the intected patients, 42 yr, was slightly
higher than the uninfected patients, 38 yr, although this did
not reach statistical significance {p = 0.19). Seventy per-
cent of the H. /n/f^W-iniected NUD patients were women
compared with 76% of the uninfected patients. African
Americans and cigarette smokers were more likely to be H.
/j_>'/o//-infectcd, although this was not statistically signifi-
cant by x^- Other entry characteristics—including a history
of prior ulcer disease and the use of alcohol, nonsteroidal
anti-inflammatory drugs, and prior ulcer medications—were
similar between the H. pylori-infected and uninfected
groups. The prevalence of types of symptoms was also
not different between the infected and uninfected groups
(Table 2).
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H. pylori Infected Patients
Pre-treatment Po8t-treatment
Fici. I. Individual and mean (± SE) pain scores at sludy entry and I
month after treatment completion in H. /n7ftn-infecled NUD patients.
At interim study analysis, it became dear that NUD
patients without H. pylori infection outnumbered infected
NUD patients 2:1. To obtain equal numbers of treated in-
fecled and uninfected patients, 36 uninfected patients were
not offered treatment in the second part of the study. Of the
remaining 31 uninfected patients, 10 dropped out. and of the
33 infected patients, 14 dropped out. Reasons for drop-out
included drug side effects in eight patients, lost or refused
follow-up in 12 patients, and unrelated medical problems in
four patients. Nineteen infected patients and 21 uninfecled
patients completed treatment and returned for the follow-up
endoscopy. H. pylori was eradicated in 13 of 19 patients
Symptom improvement was defined as an improvement
in the sum of the frequency and severity pain score of at
least three points at the time of follow-up endoscopy, which
was performed I month after completion of therapy. An
improvement in pain occurred in eight of 13 (61%) H.
/>v/rJ/7-eradicated patients and in four of six (66%) persis-
tently infected patients versus 14 of 21 (66%) noninfected
patients (Figs. 1 and 2). Uing-tcrm follow-up (26-51
months; mean, 40 months) of 21 noninfected patients
showed that nine patients were lost, six remained improved,
three became symptomatic again, and three got better de-
Pre-treatment Post-treatment
Fio, 2, Individual and mean (± SE) pain scores at sludy entry and 1
month afler treatment ampletion in noninfected NUD patients.
Spite initial treatment failure. Of the 19 //. /jy/or/-infected
patients, 13 had eradication of M pylori with a follow-up of
12-45 months (mean, 26 months). Three patients were lost,
three continued well, two relapsed, three who had failed
initial treatment improved over time, and two continued
symptomatic. Of the six persistently infected patients, two
were lost, one continued well, one relapsed, and two con-
tinued symptomatic. The response to treatment of the non-
pain symptoms (nausea/vomiting, bloating/belching/gas,
and anorexia), which were not present in all patients at study
entry, is listed in Table 3.
The mean pretreatment gastritis score (scale of 0-4) for
the H. pylori-infected patients was 2.7, and 17 of 19 had
evidence for activity (polymorphonuclcar cell infiltration).
The mean follow-up gastritis score in the eradicated patients
was 1.8, and none had persistent activity. The persistently
infected palients had a mean score of 2,8. and all had
activity. In contrast, the mean pretreatment gastritis score in
the noninfected patients was 0.1. and none had activity.
Their post-treatment score was 0.8, again without activity.
DISCUSSION
Although the role of H. pylori infection in peptic ulcer
disease is now well established, controversy continues re-
garding its relationship to non-ulcer dyspepsia (13. 14). One
of the epidemiologic links of H. pylori to NUD is the high
prevalence (50%) of infection in these patients (15, 16).
However, in this study, we demonstrate a 33% infection rate
in a group of NUD patients with a mean age of 40. This is
in agreement with Greenberg (17). who reports a 37%
infection rale in NUD patients with a mean age of 49. These
prevalence rates are identical with those reported in age-
matched asymptomatic volunteers in the U.S. (18). The
higher prevalence reported earlier may be a result of the type
of patients studied, [i.e., patients with erosive gastritis or
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TABLE 3
Treatment Respotxse of Symptom.% Other Than Pain
Symptom
HP-infected palietiis loial (HP eradicated)
In = ly (13)]





























duodenitits (19), some of whom may simply have a mild
form of peptic ulcer disease], Alternately, because the prev-
alence of H. pylori infection varies with nationality, race,
and socioeconomic class, prior data may be from popula-
tions known to have higher infection rates (20).
Clearly, conclusions concerning an association between
H. pxlori infection and NUD must come from clinical out-
come trials. Most studies to date have been flawed by
inadequate H. pylori therapy to achieve eradication (21-23),
by inclusion of patients with gastroesophageal reflux (24.
25), or by difflculty in achieving a true placebo because of
the black stools and tongue caused by bismuth treatment.
We treated our patients with 2 wk of metronidazole and 4
wk of bismuth and demonstrated eradication in 68% at I
month after completion of therapy. The superior treatment
regimens now known were not used in this study because it
was started in 1988. Although 24-hr pH studies were not
performed on all patients, the incidence of gastroesophageal
reflux disease was minimized by the exclusion of patients
wilh "reflux-like" symptoms, by the lack of prior response
to acid suppression therapy in more than 75% of our pa-
tients, and by the normal esophngeal findings at endoscopy.
instead of trying to devise an effective placebo, we treated
uninfected patients with the identical regimen without their
knowledge of the presence or absence of infection. Al-
though eight infected patients who were recruited in the
second part of the study were aware of the presence of
infection, their outcome was not different from those who
were recruited in the first half of the study. By treating
uninfected patients with the same regimen, we controlled for
the possibility that bismuth and antibiotic therapy may have
beneficial effects other than antibacterial action for NUD.
Uninfected patients seem to be an ideal control, although as
expected from previous epidemiological studies, infected
patients tended to be older and had a higher incidence of
being African American. We also found a higher incidence
of smoking in the infected patients (27% vs 15%), a result
that has been noted in previous studies (20). None of the
differences in entry characteristics between infected and
uninfeeted patients reached statistical significance.
The mean symptom scores at study enlry listed in Table
2 show that the infected and uninfected NUD patients had a
similar frequency and severity of chronic epigastric pain.
Other symptoms that were monitored throughout the study
included nausea/vomiting, bloating/belching/gas, and an-
orexia. These were not present in all patients but were of
similar severity and frequency in the infected and uninfected
patients, suggesting that H. pylori infection is not associated
with any "type" of NUD that has been previously suggested
(8). Our tailure to identify subgroups of NUD patients based
upon H. pylori status is in agreement with a recent report of
180 healthy blood donors (26). The treatment responses of
these symptoms (Table 3) were also similar between the
infected (both eradicated and persistently infected patients)
and noninfected patients. One possible exception was nau-
sea and vomiting, which seemed lo be more common in the
uninfected patients and seemed to improve more with treat-
ment. The small number of patients with these other symp-
toms, however, prevents any flrm conclusions.
A f)l-67% symptom response rate, regardless of the
presence of infection before treatment or of the success of
eradication, strongly implies that H. pyloti infection does
not play a role in causing the symptoms of NUD. Although
this seems to be a very high placebo response rate, other
functional dyspepsia trials have had similar placebo re-
sponse rates (27, 21). The high drop-out rate in our study
was disappointing but was similar in the infected and un-
infected paiients and therefore was unlikely to affect our
results. Similar problems have plagued prior NUD studies
and probably reflect characteristics of this patient popula-
tion (28). Although it has been stated that the diagnosis ol
NUD greatly outnumbers peptic ulcer disease., obtaining a
detailed history to rule out patients with probable gastro-
esophageal reflux di.sease or irritable bowel syndrome sig-
nificantly decreases the number of patients diagnosed with
NUD. This led to slow recruitment and a prolonged trial
allowing us to obtain long-term follow-up in many patients.
It has been suggested that symptomatic improvement may
be delayed for 6-12 months (29) after H. pylori eradication
as has been shown for normalization of gastric histology (9).
A recent report of 1-yr follow-up in H. /n/on-infected NUD
patients showed lower mean symptom scores in patients
remaining clear of infection versus those who were persis-
tently infected or re-infected (30), although no control group
was studied. Our similar rate of eventual disappearance of
symptoms in both the infected and uninfected patients ar-
gues against this hypothesis. The strongest criticism of our
study is the relatively small number of patients studied,
clearly insufflcient to rule out a ^-type error in our conclu-
sions. It has been estimated that a sample size of KK)
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patients in each group would be needed (10). When patients
with symptoms suggestive of gastroesophageal reflux dis-
ease or irritable bowel syndrome are carefully excluded, a
multicenter study would be required to obtain such a large
number of paiients.
Our controlled study with careful inclusion criteria, fol-
low-up for eradication, and long-term symptom outcome
results strongly suggests that chronic H. pylori infection is
not associated with the symptoms of NUD. The absence of
an association between chronic H. pylori infection and dys-
pepsia despite the association of dyspeptic symptoms with
acute infection has previously been reported (31). There
appears to be no justification for routinely obtaining random
antrai biopsies at endoscopy to identify H. pytori in patients
with non-uleer dyspepsia. Larger controlled studies with
enough power to rule out a small but potentially clinically
significant benefit from H. pylori treatment in NUD are still
needed.
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